Equities Analysts Issue Forecasts for Climb Bio Q3 Earnings

Climb Bio, Inc. (NASDAQ:CLYM) – Equities researchers at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for Climb Bio in a research note issued to investors on Monday, August 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.20) per share for the quarter, up from their previous forecast of ($0.23). HC Wainwright has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for Climb Bio’s Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.76) EPS and FY2027 earnings at ($0.98) EPS.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03.

Several other brokerages have also recently issued reports on CLYM. Truist Financial upped their target price on shares of Climb Bio from $17.00 to $25.00 and gave the company a “buy” rating in a report on Friday, August 7th. Robert W. Baird set a $21.00 price target on shares of Climb Bio in a research note on Wednesday, May 6th. Wedbush reissued an “outperform” rating and issued a $20.00 price target on shares of Climb Bio in a research report on Wednesday, August 19th. Wall Street Zen upgraded shares of Climb Bio from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, BTIG Research upped their price objective on shares of Climb Bio from $19.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, June 11th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $23.08.

Climb Bio Stock Up 8.8%

Shares of Climb Bio stock opened at $17.84 on Wednesday. Climb Bio has a 52 week low of $1.54 and a 52 week high of $18.33. The firm’s 50 day moving average is $13.59 and its two-hundred day moving average is $10.29. The firm has a market capitalization of $1.02 billion, a P/E ratio of -21.49 and a beta of 0.08.

Institutional Investors Weigh In On Climb Bio

Several large investors have recently modified their holdings of the stock. Legal & General Group Plc acquired a new stake in shares of Climb Bio during the second quarter worth $45,000. California State Teachers Retirement System acquired a new position in Climb Bio in the 2nd quarter valued at $82,000. Virtu Financial LLC acquired a new position in Climb Bio in the 4th quarter valued at $43,000. Blair William & Co. IL purchased a new position in Climb Bio during the 4th quarter worth $44,000. Finally, Balyasny Asset Management L.P. purchased a new position in Climb Bio during the 4th quarter worth $57,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.